Intech Investment Management LLC Has $1.49 Million Position in Haemonetics Corporation $HAE

Intech Investment Management LLC cut its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 32.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,589 shares of the medical instruments supplier’s stock after selling 8,900 shares during the quarter. Intech Investment Management LLC’s holdings in Haemonetics were worth $1,490,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after buying an additional 26,763 shares in the last quarter. Millennium Management LLC grew its holdings in Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after buying an additional 755,592 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in Haemonetics by 1.5% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 716,997 shares of the medical instruments supplier’s stock valued at $57,467,000 after buying an additional 10,685 shares in the last quarter. Finally, Boston Partners grew its holdings in Haemonetics by 5.1% in the 3rd quarter. Boston Partners now owns 570,891 shares of the medical instruments supplier’s stock valued at $28,017,000 after buying an additional 27,722 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HAE has been the topic of a number of research reports. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Robert W. Baird set a $67.00 price objective on Haemonetics in a report on Friday, May 8th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Citigroup upped their price objective on Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Finally, Mizuho decreased their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $77.11.

Haemonetics Stock Performance

HAE opened at $71.31 on Friday. The firm has a market cap of $3.24 billion, a P/E ratio of 35.30, a price-to-earnings-growth ratio of 1.41 and a beta of 0.56. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The business’s fifty day moving average is $60.00 and its 200-day moving average is $67.27.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts expect that Haemonetics Corporation will post 5.23 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.